Novartis settles patent case for multiple sclerosis drug

A similar action brought against another drug maker, Mylan, which is part of the Viatris group, is unaffected by the agreement and will continue

Novartis AG and its Irish affiliate Novartis Ireland Ltd said their medicine to treat relapsing-remitting MS Gilenya is "one of the most important and valuable products" in its portfolio, contributing more than US$2.7 billion of net sales in 2021. Picture: Jim Coughlan

Pharmaceutical company Novartis has settled its High Court proceedings against a rival firm alleging infringement of its patent on a drug for treating multiple sclerosis (MS).

Switzerland-based Novartis AG and its Irish affiliate Novartis Ireland Ltd said their medicine to treat relapsing-remitting MS Gilenya is "one of the most important and valuable products" in its portfolio, contributing more than US$2.7 billion of net sales in 2021.